Pro-Dex (PDEX) Projected to Post Earnings on Thursday

Key Points

• Pro-Dex (PDEX) is expected to release its Q1 2026 earnings report on October 30, 2025, with projected earnings of $0.50 per share and revenue of $15.30 million.
• In its last earnings report, Pro-Dex reported $0.36 earnings per share, falling short of the $0.47 expected by analysts, alongside revenue of $17.49 million.
• The stock price of Pro-Dex has seen minor fluctuations, closing at $26.36, and analysts currently have a consensus rating of "Moderate Buy" with a price target of $56.00.

Pro-Dex (NASDAQ:PDEX - Get Free Report) will likely be issuing its Q1 2026 results before the market opens on Thursday, October 30th. Analysts expect Pro-Dex to post earnings of $0.50 per share and revenue of $15.30 million for the quarter. Investors are encouraged to explore the company's upcoming Q1 2026 earningoverview page for the latest details on the call scheduled for Thursday, October 30, 2025 at 4:00 PM ET.

Pro-Dex (NASDAQ:PDEX - Get Free Report) last announced its quarterly earnings data on Thursday, September 4th. The medical instruments supplier reported $0.36 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.47 by ($0.11). Pro-Dex had a return on equity of 26.67% and a net margin of 13.48%.The firm had revenue of $17.49 million for the quarter, compared to analyst estimates of $17.90 million. On average, analysts expect Pro-Dex to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Pro-Dex Stock Up 1.1%

NASDAQ PDEX opened at $26.36 on Thursday. The business has a fifty day moving average price of $36.48 and a two-hundred day moving average price of $44.21. The stock has a market capitalization of $86.46 million, a PE ratio of 9.76 and a beta of -0.11. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.23 and a quick ratio of 1.71. Pro-Dex has a fifty-two week low of $23.47 and a fifty-two week high of $70.26.

Institutional Investors Weigh In On Pro-Dex

A number of institutional investors and hedge funds have recently bought and sold shares of PDEX. Geode Capital Management LLC lifted its stake in Pro-Dex by 93.2% in the second quarter. Geode Capital Management LLC now owns 51,668 shares of the medical instruments supplier's stock valued at $2,255,000 after purchasing an additional 24,927 shares during the last quarter. JPMorgan Chase & Co. raised its stake in Pro-Dex by 67.7% in the 2nd quarter. JPMorgan Chase & Co. now owns 35,877 shares of the medical instruments supplier's stock valued at $1,566,000 after acquiring an additional 14,479 shares during the period. Jane Street Group LLC purchased a new stake in Pro-Dex during the first quarter valued at about $321,000. Osaic Holdings Inc. boosted its position in Pro-Dex by 23.6% during the second quarter. Osaic Holdings Inc. now owns 7,120 shares of the medical instruments supplier's stock worth $311,000 after purchasing an additional 1,360 shares during the period. Finally, Cubist Systematic Strategies LLC purchased a new position in shares of Pro-Dex in the first quarter worth about $170,000. 15.28% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. Wall Street Zen cut shares of Pro-Dex from a "buy" rating to a "hold" rating in a research note on Saturday, August 16th. Weiss Ratings restated a "hold (c+)" rating on shares of Pro-Dex in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $56.00.

About Pro-Dex

Pro-Dex, Inc designs, develops, manufactures, and sells powered surgical instruments for medical device original equipment manufacturers worldwide. The company offers autoclavable, battery-powered and electric, and multi-function surgical drivers and shavers that are primarily used in the orthopedic, thoracic, and craniomaxillofacial markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.